{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:36:10Z","timestamp":1789385770096,"version":"build-2803163510"},"reference-count":114,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,5,12]]},"DOI":"10.1080\/10428194.2023.2196593","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T05:45:32Z","timestamp":1682055932000},"page":"1063-1081","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":50,"title":["Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy"],"prefix":"10.1080","volume":"64","author":[{"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fleischman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Medicine, University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000279"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1925"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090299"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050984"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"CIT0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, version 1. 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477."},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"CIT0013","volume-title":"Full prescribing information","author":"JAKAFI\u00ae (ruxolitinib).","year":"2023"},{"key":"CIT0014","first-page":"75","volume":"8","author":"Raedler LA.","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16462"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1845334"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006889"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04682-x"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34103"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006006"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1146950"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151449"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010298.pub2"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34205"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02246"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00140-5"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482232"},{"key":"CIT0032","doi-asserted-by":"crossref","unstructured":"Oh S, Verstovsek S, Gotlib J, et\u00a0al. Bone marrow fibrosis changes do not correlate with efficacy outcomes in myelofibrosis: analysis of more than 300 JAK inhibitor-naive patients treated with momelotinib or ruxolitinib. Presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, New Orleans, LA. 2022.","DOI":"10.1182\/blood-2022-160409"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0379-y"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0585-5"},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, et\u00a0al. Ruxolitinib (RUX) induced meaningful and directional changes in the bone marrow microenvironment of patients with myelofibrosis enrolled in the COMFORT-I study. Presented at the 61st American Society of Hematology Annual Meeting & Exposition, Orlando, FL. 2019.","DOI":"10.1182\/blood-2019-124343"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.08.002"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000424"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18674"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13379"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01261-x"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.025"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1159\/000520440"},{"key":"CIT0047","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, version 3; 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477."},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01252-7"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S53348"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-79"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194750"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01107-y"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.37201\/req\/054.2022"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664"},{"key":"CIT0059","volume-title":"Full prescribing information","author":"Inrebic\u00ae (fedratinib).","year":"2019"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"CIT0062","volume-title":"Full prescribing information","author":"VONJO\u2122 (pacritinib).","year":"2022"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1749606"},{"key":"CIT0064","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hematopoietic Cell Transplantation (HCT), version 2; 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1501"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.272"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.218"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.148"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1967256"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810739"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-897637"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.10.004"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.04.005"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162417"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.5045\/br.2021.2021101"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16729"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389469"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.078899"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S110702"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01439-2"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5223"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26058"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00526-z"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222944"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.002"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-414631"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26129"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.10.966"},{"key":"CIT0100","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18207"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"CIT0102","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Kremyanskaya M, Patriarca A, et\u00a0al. BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis\u2014JAK inhibitor-naive or with suboptimal response to ruxolitinib\u2014preliminary data from the manifest study. Presented at the European Hematology Association 2022 Hybrid Congress, Vienna\/Virtual; 2022.","DOI":"10.1097\/01.HS9.0000843684.97625.7e"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT162"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-846626"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02188"},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.06.005"},{"key":"CIT0107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122546"},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137265"},{"issue":"1","key":"CIT0109","first-page":"255","volume":"130","author":"Bose P","year":"2017","journal-title":"Blood"},{"key":"CIT0110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127661"},{"key":"CIT0111","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3026"},{"key":"CIT0112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7060"},{"key":"CIT0113","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1751121"},{"key":"CIT0114","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010068"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2196593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:52:20Z","timestamp":1686534740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2196593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5,12]]}},"alternative-id":["10.1080\/10428194.2023.2196593"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2196593","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}